Sotorasib has shown efficacy primarily in treating KRAS G12C-mutated cancers. The most significant clinical benefit has been observed in non-small cell lung cancer (NSCLC), which accounts for about 85% of all lung cancers. Additionally, sotorasib is being investigated in clinical trials for its effectiveness in other cancers harboring the KRAS G12C mutation, including colorectal cancer and certain types of pancreatic cancer.
